Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELYAGE: Rituximab + Lenalidomide vs Rituximab + Chemotherapy in Elderly Relapsed DLBCL
2019-002499-14Phase 2Terminated
- Sponsor
- CHU Amiens-Picardie
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of rituximab, lenalidomide, gemcitabine, oxaliplatin and bendamustine in diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by CHU Amiens-Picardie. Primary endpoint: Progression-free survival with maintenance of autonomy at 6 months. Started Mar 2021; status: terminated.
02
Drugs
rituximablenalidomidegemcitabineoxaliplatinbendamustine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2019-002499-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002499-14.